Kathleen Clarence-Smith
Founder at Km Pharmaceutical Consulting LLC
Profile
Kathleen E.
Clarence-Smith is the founder of Prestwick Scientific Capital, Inc. (founded in 1996), OXIS Biotech, Inc. (founded in 2014), Georgetown Translational Pharmaceuticals, Inc. (founded in 2015), and Chase Pharmaceuticals Corp.
(founded in 2007).
She held the title of Chief Medical Officer at Chase Pharmaceuticals Corp.
from 2014 to 2016.
Dr. Clarence-Smith is also the founder of Prestwick Chemical, Inc., Prestwick Pharmaceuticals, Inc., and Km Pharmaceutical Consulting LLC.
She currently holds positions as Chairman at Chase Therapeutics Corp., Director at Riverside Pharmaceuticals Corp., Director at Westhaven Therapeutics Corp., Director at DAS Therapeutics, Inc., and Member at the American Academy of Neurology (since 1990).
Her former positions include Vice Chairman & President-Neurology Division at GT Biopharma, Inc. (2017-2018), Senior Director-CNS Clinical Development at Hoffmann-La Roche, Inc., and Research Analyst at Stanford Group Co. She was also the Head-CNS Group at Sanofi from 1980 to 1987.
Dr. Clarence-Smith obtained a doctorate degree from Université François-Rabelais de Tours.
Kathleen Clarence-Smith active positions
| Companies | Position | Start |
|---|---|---|
| Km Pharmaceutical Consulting LLC | Founder | - |
Chase Therapeutics Corp.
 Chase Therapeutics Corp. Pharmaceuticals: MajorHealth Technology Chase Therapeutics Corp. operates as healthcare company. The company was founded in 2017 and is headquartered in Washington, DC. | Chairman | - |
American Academy of Neurology
 American Academy of Neurology Miscellaneous Commercial ServicesCommercial Services American Academy of Neurology operates a professional society which represents neurologists and neuroscientists. The company was founded in 1948 and is headquartered in Minneapolis, MN. | Corporate Officer/Principal | 1989-12-31 |
| Riverside Pharmaceuticals Corp. | Director/Board Member | - |
| Westhaven Therapeutics Corp. | Director/Board Member | - |
DAS Therapeutics, Inc.
 DAS Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology DAS Therapeutics, Inc. is a clinical stage pharmaceutical company. It acquires and develops assets for conditions overlooked or under-served by current treatment approaches to improve patient outcomes. The company was founded by Raimonds Dzelme, Christina Cognata-Smith and Michael Nemmers in 2016 and is headquartered in Boston, MA. | Director/Board Member | - |
Former positions of Kathleen Clarence-Smith
| Companies | Position | End |
|---|---|---|
| GT BIOPHARMA, INC. | Chief Executive Officer | - |
Chase Pharmaceuticals Corp.
 Chase Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Chase Pharmaceuticals Corp. develops novel medications for the treatment of Alzheimer’s disease. It focuses on pharmaceuticals for Alzheimer type dementia, which include oral medications such as its lead product, CPC-201, as well as CPC 252 for transdermal administration. The company was founded by Thomas N. Chase and Kathleen Clarence-Smith in 2007 and is headquartered in Washington, DC. | Founder | 2015-12-31 |
Stanford Group Co.
 Stanford Group Co. Investment Banks/BrokersFinance Founded in 1932, Stanford Group Co. is a broker/dealer headquartered in Houston, Texas with offices nationwide. They are a subsidiary of Stanford Financial Services, Inc. and their ultimate parent is CBaySystems Holdings Ltd. The firm offers a full range of brokerage services for both domestic and international clients. They are a member of the NASD and the SIPC. Stanford's research includes both institutional equity research and Washington-focused policy research, offering a perspective on individual companies, sector-specific topics and national policy. Their equity analysts offer insight and opinions on companies in the consumer/retail, media, energy, financial institutions, healthcare, technology and water/environment sectors, targeting small- and mid-cap companies. Their policy analysts deliver investment relevant insights across a broad range of sectors, including geopolitics, international/trade, Federal Reserve board policy, health care (including services, medical devices and pharmaceuticals, telecom, media, financial services, water/environment, agribusiness/tobacco, energy) and technology (including information technology services, homeland security and biometrics/emerging technologies). | Analyst-Equity | 2009-01-31 |
| ░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░ ░░░░░░░░ ░░░░ | ░░░░░░░ | - |
Training of Kathleen Clarence-Smith
| Université François-Rabelais de Tours | Doctorate Degree |
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| GT BIOPHARMA, INC. | Health Technology |
| SANOFI | Commercial Services |
| Private companies | 14 |
|---|---|
Stanford Group Co.
Stanford Group Co. Investment Banks/BrokersFinance Founded in 1932, Stanford Group Co. is a broker/dealer headquartered in Houston, Texas with offices nationwide. They are a subsidiary of Stanford Financial Services, Inc. and their ultimate parent is CBaySystems Holdings Ltd. The firm offers a full range of brokerage services for both domestic and international clients. They are a member of the NASD and the SIPC. Stanford's research includes both institutional equity research and Washington-focused policy research, offering a perspective on individual companies, sector-specific topics and national policy. Their equity analysts offer insight and opinions on companies in the consumer/retail, media, energy, financial institutions, healthcare, technology and water/environment sectors, targeting small- and mid-cap companies. Their policy analysts deliver investment relevant insights across a broad range of sectors, including geopolitics, international/trade, Federal Reserve board policy, health care (including services, medical devices and pharmaceuticals, telecom, media, financial services, water/environment, agribusiness/tobacco, energy) and technology (including information technology services, homeland security and biometrics/emerging technologies). | Finance |
Prestwick Pharmaceuticals, Inc.
 Prestwick Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Prestwick Pharmaceuticals, Inc. develops drugs for diseases related to the central nervous system. Its drugs are used in curing diseases such as Huntington's, Parkinson's, restless legs syndrome, schizophrenia, autism, Alzheimer's, and sleep apnea diseases. The company was founded in 2002 and is headquartered in Washington DC. | Health Technology |
Chase Pharmaceuticals Corp.
Chase Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Chase Pharmaceuticals Corp. develops novel medications for the treatment of Alzheimer’s disease. It focuses on pharmaceuticals for Alzheimer type dementia, which include oral medications such as its lead product, CPC-201, as well as CPC 252 for transdermal administration. The company was founded by Thomas N. Chase and Kathleen Clarence-Smith in 2007 and is headquartered in Washington, DC. | Health Technology |
Hoffmann-La Roche, Inc.
 Hoffmann-La Roche, Inc. BiotechnologyHealth Technology Hoffmann-La Roche, Inc. manufactures pharmaceutical drugs. Its products include influenza fighter Tamiflu, controversial acne medication Accutane, HIV inhibitor Fuzeon, obesity drug Xenical, and hepatitis C therapy Pegasys. The company was founded in 1896 Roche and is headquartered in Nutley, NJ. | Health Technology |
American Academy of Neurology
American Academy of Neurology Miscellaneous Commercial ServicesCommercial Services American Academy of Neurology operates a professional society which represents neurologists and neuroscientists. The company was founded in 1948 and is headquartered in Minneapolis, MN. | Commercial Services |
| Km Pharmaceutical Consulting LLC | |
| Prestwick Scientific Capital, Inc. | |
| Prestwick Chemical, Inc. | |
OXIS Biotech, Inc.
 OXIS Biotech, Inc. BiotechnologyHealth Technology OXIS Biotech, Inc. develops innovative drugs for the treatment of cancer. It also focuses on developing drugs for the treatment of other unmet medical needs. The company was founded by Kathleen E. Clarence-Smith on September 26, 2014 and is headquartered in Tampa, FL. | Health Technology |
Georgetown Translational Pharmaceuticals, Inc.
 Georgetown Translational Pharmaceuticals, Inc. Hospital/Nursing ManagementHealth Services Georgetown Translational Pharmaceuticals, Inc. provides treatment for neuropathic pain, refractory epilepsies, the symptoms of myasthenia gravis, and motion sickness. The company was founded by Kathleen Clarence-Smith and Mark J. Silverman and is headquartered in United States. | Health Services |
Chase Therapeutics Corp.
Chase Therapeutics Corp. Pharmaceuticals: MajorHealth Technology Chase Therapeutics Corp. operates as healthcare company. The company was founded in 2017 and is headquartered in Washington, DC. | Health Technology |
| Riverside Pharmaceuticals Corp. | Miscellaneous |
| Westhaven Therapeutics Corp. | |
DAS Therapeutics, Inc.
DAS Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology DAS Therapeutics, Inc. is a clinical stage pharmaceutical company. It acquires and develops assets for conditions overlooked or under-served by current treatment approaches to improve patient outcomes. The company was founded by Raimonds Dzelme, Christina Cognata-Smith and Michael Nemmers in 2016 and is headquartered in Boston, MA. | Health Technology |
- Stock Market
- Insiders
- Kathleen Clarence-Smith